System and method for monitoring blood glucose levels using an implantable medical device

• US 20060100494A1
• Filed: 12/20/2005
• Published: 05/11/2006
• Est. Priority Date: 10/21/2002
• Status: Active Grant

• Current Assignee: Mark W. Kroll
• Original Assignee: Mark W. Kroll
• Inventors: Kroll, Mark W.
• Granted Patent: US 7,680,529 B2
• Time in Patent Office: Days
• US Class Current: 600/365
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/355 Detecting T-waves
• CPC Class Codes: A61B 5/36 Detecting PQ interval, PR interval or QT interval
• CPC Class Codes: A61N 1/3702 Physiological parameters A61N1/365 takes precedence; evoked response A61N1/371

Abstract

T-wave amplitude and QT interval are derived from patient cardiac signals. Then blood glucose levels are determined based on a combination of the T-wave amplitude and the QT interval. By using a combination of both T-wave-based and QT interval-based signals, blood glucose levels can be reliably detected throughout a wide range of blood glucose levels. Once the blood glucose level has been detected, the implanted device compares the blood glucose level against upper and lower acceptable bounds and appropriate warning signals are generated if the level falls outside the bounds. In one example, wherein an implantable insulin pump is additionally provided, the pump is controlled based on the detected blood glucose level to maintain glucose levels within an acceptable range. A calibration technique is also provided for determining patient-specific parameters for use in the detection of blood glucose levels.

Claims

1. A method of monitoring blood glucose levels using an implantable medical device, the method comprising:

detecting patient cardiac signals;

detecting a first feature from the cardiac signals, the first feature known to exhibit a substantially bimodal response as a function of blood glucose levels;

detecting at least one additional feature from the cardiac signals, the additional feature known to exhibit a substantially monotonic response as a function of blood glucose levels; and

deriving a blood glucose level based on a combination of the first feature and the at least one additional feature.

2. The method of claim 1 wherein the first feature comprises a T-wave amplitude.

3. The method of claim 1 wherein the first feature comprises a T-wave amplitude fraction.

4. The method of claim 1 wherein the additional feature comprises a QT interval.

5. The method of claim 1 wherein the additional feature comprises heart rate variability.

6. The method of claim 1 wherein the additional feature comprises QT dispersion.

7. The method of claim 1 wherein the additional feature comprises at least one of RT and ST interval.

8. An implantable medical device comprising:

a cardiac signal detection unit operative to detect a first feature of a cardiac signal that exhibits a substantially bimodal response as a function of blood glucose levels and at least one additional feature of the cardiac signal that exhibits a substantially monotonic response as a function of blood glucose levels; and

a processor operative to derive a blood glucose level based on a combination of the first feature and the at least one additional feature.

9. The device of claim 8 wherein the first feature is T-wave amplitude and the at least one additional feature comprises one of QT interval, heart rate variability, QT dispersion, RT interval and ST interval.

10. The device of claim 8 wherein the processor is operative to derive a blood glucose level by applying the first feature and the at least one additional feature to a linear function.

11. An implantable medical device comprising:

a detection unit operative to detect a QT interval of a cardiac signal; and

a processor operative to derive a corrected QT interval based on the detected QT interval and to derive a blood glucose level based on the corrected QT interval.

12. The device of claim 11 wherein the processor is operative to provide blood glucose levels within a predetermined range of levels.